Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of a condition in a mammal with administration of compounds and methods of use

A mammalian and compound technology, applied in the direction of carbohydrate active ingredients, medical preparations containing active ingredients, drug combinations, etc., can solve the problem of not preventing or slowing the progression of OA

Inactive Publication Date: 2008-03-12
OPTIMER PHARMA +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] Due to the many side effects of these current OA treatments and the fact that they do not lead to true remission of OA because they do not prevent or slow down the progression of OA, there is a great need for safer and more effective treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of a condition in a mammal with administration of compounds and methods of use
  • Treatment of a condition in a mammal with administration of compounds and methods of use
  • Treatment of a condition in a mammal with administration of compounds and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Treatment of cultured osteoarthritic human articular chondrocytes with amino sugars

[0145]Human osteoarthritic cartilage was obtained from an informed donor following routine total knee replacement. Articular cartilage from the femoral condyles and tibial plateaus were aseptically dissected. Cartilage scrapings were harvested and placed in tissue culture medium (DMEM, 10% FBS, penicillin, streptomycin) and stored at 4°C until they were processed.

[0146] After sequential digestion with pronase (Roche, 10 g / l) for 30 minutes and collagenase type IV (Sigma, 1 g / l) for 6 hours, both digestions were carried out in 0.9% NaCl, Chondrocytes were isolated from cartilage. In DMEM (BioWhittaker) supplemented with 10% fetal bovine serum (BioWhittaker), 60 U / ml penicillin, 60 μg / ml streptomycin and 2 mmol / l glutamine (BioWhittaker) at 37 °C in the presence of 5% CO 2 chondrocytes were allowed to grow to confluence.

[0147] Experiment with first or second passage cells. Chondrocy...

Embodiment 2

Effects of amino sugars on NO induced by IL-1β in cultured chondrocytes

[0148] IL-1β-induced inflammatory mediator·NO was measured according to the method of Griess reaction (Hevel, et. al. Methods Enzymol. 233:250) and by protein ELISA (R&D Systems, Minneapolis, MN).

[0149] Amino sugars such as GlcN and GlcNAc are known to inhibit IL-1β and TNFα-induced nitric oxide (·NO) production in osteoarthritic human articular chondrocytes (PCT Publication WO 02 / 078445A1). Therefore, the effect of the amino sugar derivatives of the present invention on IL-1β-induced NO production will be measured and compared according to the Griess reaction method, and the amino sugar derivatives include but not limited to derivatives of glucosamine, semi-glucosamine Derivatives of lactosamine, derivatives of cyclodol and derivatives of iminocyclitol.

[0150] In an oxygenated solution, NO decomposes to form NO 2 - and NO 3 - , as shown in equations (1)-(3).

2 NO+O 2 →2·NO 2 ...

Embodiment 3

Effects of amino sugars on IGF-stimulated synthesis of sulfated glycosaminoglycans (SGAG)

[0155] Basal sulfated glycosaminoglycan (SGAG) synthesis and IGF-stimulated sulfated glycan synthesis in vitro and in vivo can be assayed by methods similar to those described elsewhere (Scharstuhl et al. Ann. Rheum. Dis. 61: 1095). Saminoglycan (SGAG) synthesis. Can be measured in the extracellular fraction 35 Levels of incorporation of S-sodium sulfate (ICN Radiochemicals, Irvine, CA) into SAGA. This can be done in the presence or absence of aminosugar derivatives of the invention, including but not limited to derivatives of glucosamine, galactosamine, cyclodol and Derivatives of iminocyclitols.

In vivo SGAG synthesis:

[0156] The right knee joints of mice aged 3 to 18 months can be injected with IGF in PBS supplemented with 0.1% bovine serum albumin and amino sugar derivatives of the present invention, including but not It is limited to derivatives of glucosamine, galactosa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to methods of treating, preventing, and lessening the severity of conditions or diseases selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation (''OA and related disorders'') with administration of an aminosugar derivative and pharmaceutically acceptable salts thereof.

Description

[0001] related application [0001] This application claims the benefit of US Provisional Application Serial No. 60 / 524,698, filed November 24, 2003, which is hereby incorporated by reference in its entirety. technical field [0002] The present invention relates to methods of treating, preventing and reducing the severity of a condition or disease selected from osteoarthritis (OA) by administering aminosugar derivatives and pharmaceutically acceptable salts thereof ), rheumatoid arthritis, synovitis, subchondral bone edema (subchondral bone edema) and cartilage degeneration (cartilage degradation) (hereinafter, referred to as "OA and related disorders"). Background technique [0003] Osteoarthritis (OA) is a common joint disease with important social implications (Lawrence et al., (1998) Arthritis Rheum. 41: 778; Gabriel et al., (1997) J. Rheumatol. 24: 719 ; March et al., (1997) Baillieres Clin. Rheumatol. 11:817). Drug classes used to treat OA include acetaminophen, non...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/70A61K
CPCA61K31/16A61K31/7052A61K31/70A61K31/7008A61K31/13A61P19/02A61P29/00A61P43/00
Inventor Y·市川F·W·奥库穆M·洛茨
Owner OPTIMER PHARMA